Riskpilot← Back to searchSign inGet full accessCF Läkarkonsult AB
ABActiveOrg 5591890156Arbetargatan 5 B Lgh 1101Medical specialists activities · NACE 8622Est. 20180 employees
Revenue 2024
SEK 1,5M
+224% vs 2023
EBITDA margin
84.0%
+381% vs 2023
Equity ratio
69.4%
Financial strength
Net profit 2024
SEK 739K
+266% vs 2023
| Revenue | SEK 1,5M | +224% |
| EBITDA | SEK 1,2M | +381% |
| Net profit | SEK 739K | +266% |
| Total assets | SEK 1,5M | +194% |
| Equity | SEK 1M | +113% |
| Employees | 0 | — |
Legal name
CF Läkarkonsult AB
Org number
5591890156
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
28 december 2018
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Aktiebolaget ska bedriva medicinsk vård samt kapitalförvaltning och därmed förenlig verksamhet. Bolaget ska även bedriva byggverksamhet och därmed förenlig verksamhet.
Address
Arbetargatan 5 B Lgh 1101
Email
cf.radberg@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 324 | 400 | 475 | 453 | 1 465 |
| Staff expenses | — | — | −16 | −2 | — |
| EBITDA | 288 | 344 | 416 | 256 | 1 231 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | 288 | 344 | 416 | 256 | 1 231 |
| Net financials | — | −1 | −1 | −1 | — |
| Profit before tax | 288 | 343 | 415 | 255 | 931 |
| Tax | −62 | −71 | −86 | −53 | −192 |
| Net profit | 226 | 272 | 330 | 202 | 739 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 549 | 572 | 664 | 498 | 1 463 |
| Equity | 280 | 372 | 472 | 477 | 1 016 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 269 | 200 | 192 | 21 | 147 |
| Total debt | 269 | 200 | 192 | 21 | 147 |
EBITDA margin
84.0%
This company
15.8%
Market median
+432% vs market
20202024
Equity ratio
69.4%
This company
38.2%
Market median
+82% vs market
20202024
Return on equity
72.7%
This company
18.4%
Market median
+295% vs market
20202024
Net profit margin
50.4%
This company
8.1%
Market median
+522% vs market
20202024
Asset turnover
1.00×
This company
1.12×
Market median
+11% vs market
20202024
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CF Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Carl Fredrik Rådberg | Board of Directors | 0 companies |
| Gunilla Elisabeth Rådberg | Board of Directors | 0 companies |
| Greta Gabriella Elisabet Rådberg | Deputy Board Member | 0 companies |